Targeting interleukin‐1 in the treatment of rheumatoid arthritis
Open Access
- 7 March 2002
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (3) , 574-578
- https://doi.org/10.1002/art.10168
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.Journal of Clinical Investigation, 1995
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonistNature, 1990
- Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitorNature, 1990
- SPECIFIC INTERLEUKIN-1 INHIBITOR IN SERUM AND URINE OF CHILDREN WITH SYSTEMIC JUVENILE CHRONIC ARTHRITISThe Lancet, 1987
- Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s).Journal of Clinical Investigation, 1986
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980